About Trasylol

Trasylol, manufactured by Bayer, is an anti-bleeding drug that was used during heart surgery for 14 years before being pulled from the market in November 2007.

Two studies recently published in the New England Journal of Medicine confirm the findings of a Trasylol study published January 2006 that showed patients treated with Trasylol have twice the rate of kidney failure and an increased risk of heart attacks, heart failure, strokes, encephalopathy, and death.

In September 2006, the FDA held hearings to investigate the safety and risks of Trasylol. During the hearings, Bayer withheld data from its own Trasylol study that confirmed the risks of Trasylol revealed by the January 2006 study.

Trasylol was pulled from the market in November 2007 when a Trasylol study had to be stopped early because of the markedly increased death rate of patients in the study group (the ones given Trasylol).

It now is estimated that over 22,000 lives could have been saved had Trasylol been taken off the market in January 2006 when the risks became known (and confirmed in a study withheld by Bayer from the FDA).

One-third of all heart surgery patients from December 1993 to November 2007 were given Trasylol, most without their knowledge.

If you or a loved one had heart surgery and later suffered kidney problems, renal failure, heart attack, stroke, or congestive heart failure, you may be entitled to money damages. For a free consultation with a top Trasylol injury lawyer, contact us today. Let us help you get the compensation you deserve.